Drug intelligence / Profile preview

controlled-ileal-release nicotinic acid

Development stage: Phase 2
Lead developer: Universitätsklinikum Schleswig-Holstein
Modality: Small Molecules
Administration: Oral

Overview

Controlled-ileal-release nicotinic acid (CIR-NA) is a specific formulation of nicotinic acid (niacin) designed for targeted release in the ileum. Nicotinic acid is a B vitamin used therapeutically primarily to treat hyperlipidemia, dyslipidemia, hypertriglyceridemia, and niacin deficiency. It works by decreasing levels of very low density lipoproteins and low density lipoproteins, while increasing levels of high density lipoproteins. This specific formulation is being investigated for its effects on the gut microbiome and insulin sensitivity.

Brand names: NiaspanSlo-NiacinNiacor
Other names: niacinnicotinic acid

Targets

HCAR2 (Hydroxycarboxylic acid receptor 2)HCAR3 (Hydroxycarboxylic acid receptor 3)

Beyond the preview

Go deeper on controlled-ileal-release nicotinic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on controlled-ileal-release nicotinic acid.

Explore the full profile